| [1] |
Hegodus L, Bonnema SJ, Bennedbsek FN, et al. Management of simple nodular goiter:current status and future perspectives.Endocr Rev, 2003, 24(1):102-132.
|
| [2] |
Meller J, Siefker U, Hamsnn A, et al. Incidence of radioiodine induced Graves' disease in patients with multinodular toxic goiter.Exp Clin Endocrinol Diabetes, 2006, 114(5):235-239.
|
| [3] |
Wallaschofsld H, Muller D, Georgi P, et al. Induction of TSH-receptor antibodies in patients with toxic multinodular goitre by radioiodine treatment. Horm Metab Res, 2002, 34(1):36-39.
|
| [4] |
Cseke B, Balazs C. Development of Basedows disease after radioiodine therapy for nodular goiter. Orv Hetil, 2003, 144(47):2327-2329.
|
| [5] |
Schmidt M, Gorbauch E, Dietlein M, et al. Incidence of postradioiodine immunogenic hyperthyroidism/Graves' disease in relation to a temporary increase in thyrotropin receptor antibodies after radioiodine therapy for autonomous thyroid disease. Thyroid, 2006, 16(3):281-288.
|
| [6] |
Dunkelmann S, Wolf R, Koch A, et al. Incidence of radiationinduced Graves' disease in patients treated with radioiodine for thyroid autonomy before and after introduction of a high-sensitivity TSH receptor antibody assay. Eur J Nucl Med Mol Imaging, 2004,31(10):1428-1434.
|
| [7] |
Nygoard B, Knudsen JH, Hegedus L, et al. Thyrotropin receptor antibodies and Graves' disease, a side-effect of 131Ⅰ treatment in patients with nontoxic goiter. J Clin Endocrinol Metab, 1997, 82(9):2926-2930.
|
| [8] |
Nygaard B, Faber J, Veie A, et al. Transition of nodular toxic goiter to autoimmune hyperthyroidism triggered by 131Ⅰ therapy.Thyroid, 1999, 9(5):477-481.
|
| [9] |
Weiss M, Gorges R, Hirsch C, et al. Incidence of immunogenic hyperthyroidism after radioiodine therapy of focal thyroid gland autonomy. Results of a multicenter study. Med Klin (Munich), 1999,94(5):239-244.
|
| [10] |
Giovanella L, Ceriani L, C, arancini S. Evaluation of the 2nd generation radio-receptional assay for anti-TSH receptor antibodies(TRAb) in autoimmune thyroid diseases. Q J Nucl Med, 2001, 45(1):115-119.
|
| [11] |
Rapoport B, McLachlan S M. Thyroid autoimmunity. J Clin Invest, 2001, 108(9):1253-1259.
|
| [12] |
Custro N, Ganci A, Scafidi V, et al. Relapses of hyperthyroidism in patients treated with radioiodine for nodular toxic goiter:relat-ion to thyroid autoimmunjty. J Endocrinol Invest, 2003, 26(2):106-110.
|
| [13] |
Pedersen IB, Knudsen N, Jorgensen T, et al. Thyroid peroxidase and thyroglobin autoanfibodies in a large survey of populations with mild and moderate iodine deficiency. Clin Endocrinol (Oxt),2003, 58(1):36-42.
|
| [14] |
Hollower JG, Staehling NW, Flanders WD, et al. Serum thyrotropin, thyrox-ine and thyroid antibodies in the United States population (1988-1994):NHANES IL J Clin Endocrinol Metab,2002, 87(2):489-499.
|
| [15] |
Hirsch C, Spyra JL, Langhammer HR, et al. Occurrence of immune hyperthyroidism after radioiodine therapy of autonomous goiter.Med Klin (Munich), 1997, 92(3):130-137.
|